UA77775C2 - 2,3 diaril-pyparazolidine derivatives inhibiting enzymes degrading neurotensin, pharmaceutical conmposition - Google Patents
2,3 diaril-pyparazolidine derivatives inhibiting enzymes degrading neurotensin, pharmaceutical conmposition Download PDFInfo
- Publication number
- UA77775C2 UA77775C2 UA20041008453A UA20041008453A UA77775C2 UA 77775 C2 UA77775 C2 UA 77775C2 UA 20041008453 A UA20041008453 A UA 20041008453A UA 20041008453 A UA20041008453 A UA 20041008453A UA 77775 C2 UA77775 C2 UA 77775C2
- Authority
- UA
- Ukraine
- Prior art keywords
- alkyl
- hydrogen
- nitrogen
- carbon
- halogen
- Prior art date
Links
- 102000050267 Neurotensin Human genes 0.000 title claims abstract description 11
- 101800001814 Neurotensin Proteins 0.000 title claims abstract description 11
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 title claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 title abstract description 6
- 102000004190 Enzymes Human genes 0.000 title abstract description 6
- 230000002401 inhibitory effect Effects 0.000 title abstract description 4
- 230000000593 degrading effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 230000001404 mediated effect Effects 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 230000036540 impulse transmission Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 125000004963 sulfonylalkyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000004209 confusion Diseases 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000002274 desiccant Substances 0.000 description 10
- 239000003480 eluent Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 5
- -1 2-chloro-1,3-dimethylimidazolinium hexafluorophosphate Chemical compound 0.000 description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 5
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000013049 sediment Substances 0.000 description 5
- WXUAQHNMJWJLTG-UHFFFAOYSA-N 2-methylbutanedioic acid Chemical compound OC(=O)C(C)CC(O)=O WXUAQHNMJWJLTG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 229940014800 succinic anhydride Drugs 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- VSKMVAJFNWCWPG-UHFFFAOYSA-N n-methyladamantan-2-amine Chemical compound C1C(C2)CC3CC1C(NC)C2C3 VSKMVAJFNWCWPG-UHFFFAOYSA-N 0.000 description 2
- 150000003218 pyrazolidines Chemical class 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- PENWGQNPFRRVQI-UHFFFAOYSA-N (2-fluorophenyl)hydrazine Chemical compound NNC1=CC=CC=C1F PENWGQNPFRRVQI-UHFFFAOYSA-N 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- YNQXOOPPJWSXMW-UHFFFAOYSA-N 1-ethenyl-2-fluorobenzene Chemical compound FC1=CC=CC=C1C=C YNQXOOPPJWSXMW-UHFFFAOYSA-N 0.000 description 1
- VHQIDCCICPFCOG-UHFFFAOYSA-N 2-isocyanatoadamantane Chemical compound C1C(C2)CC3CC1C(N=C=O)C2C3 VHQIDCCICPFCOG-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- OAMWNDMMJLINIH-UHFFFAOYSA-N 4-amino-3-methyl-4-oxobutanoic acid Chemical compound NC(=O)C(C)CC(O)=O OAMWNDMMJLINIH-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101000616562 Danio rerio Sonic hedgehog protein A Proteins 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001077660 Molo Species 0.000 description 1
- 108090000812 Neurolysin Proteins 0.000 description 1
- 102100023072 Neurolysin, mitochondrial Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- QZWNXXINFABALM-UHFFFAOYSA-N adamantan-2-amine Chemical compound C1C(C2)CC3CC1C(N)C2C3 QZWNXXINFABALM-UHFFFAOYSA-N 0.000 description 1
- IYKFYARMMIESOX-UHFFFAOYSA-N adamantanone Chemical compound C1C(C2)CC3CC1C(=O)C2C3 IYKFYARMMIESOX-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013504 emergency use authorization Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- RIVIDPPYRINTTH-UHFFFAOYSA-N n-ethylpropan-2-amine Chemical compound CCNC(C)C RIVIDPPYRINTTH-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108010032563 oligopeptidase Proteins 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- BULVZWIRKLYCBC-UHFFFAOYSA-N phorate Chemical compound CCOP(=S)(OCC)SCSCC BULVZWIRKLYCBC-UHFFFAOYSA-N 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/04—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02076482 | 2002-03-18 | ||
| PCT/EP2003/050064 WO2003078400A1 (en) | 2002-03-18 | 2003-03-17 | Neurotensin active 2,3-diaryl-pyrazolidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA77775C2 true UA77775C2 (en) | 2007-01-15 |
Family
ID=27838122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041008453A UA77775C2 (en) | 2002-03-18 | 2003-03-17 | 2,3 diaril-pyparazolidine derivatives inhibiting enzymes degrading neurotensin, pharmaceutical conmposition |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7186741B2 (es) |
| EP (1) | EP1487802B1 (es) |
| JP (1) | JP4484525B2 (es) |
| KR (1) | KR20040106290A (es) |
| CN (1) | CN100509788C (es) |
| AR (1) | AR038967A1 (es) |
| AT (1) | ATE493390T1 (es) |
| AU (1) | AU2003219165B2 (es) |
| BR (1) | BR0306149A (es) |
| CA (1) | CA2462694C (es) |
| DE (1) | DE60335525D1 (es) |
| DK (1) | DK1487802T3 (es) |
| ES (1) | ES2358894T3 (es) |
| HK (1) | HK1070646A1 (es) |
| HR (1) | HRP20040275A2 (es) |
| IL (1) | IL160944A0 (es) |
| MX (1) | MXPA04004743A (es) |
| NO (1) | NO20044405L (es) |
| PL (1) | PL371440A1 (es) |
| PT (1) | PT1487802E (es) |
| RU (1) | RU2304578C2 (es) |
| SI (1) | SI1487802T1 (es) |
| UA (1) | UA77775C2 (es) |
| WO (1) | WO2003078400A1 (es) |
| ZA (1) | ZA200404741B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| US10377718B2 (en) | 2014-06-06 | 2019-08-13 | Research Triangle Institute | Apelin receptor (APJ) agonists and uses thereof |
| EP3386976A1 (en) | 2015-12-09 | 2018-10-17 | Research Triangle Institute, International | Improved apelin receptor (apj) agonists and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3712365A1 (de) | 1987-04-11 | 1988-10-27 | Hoechst Ag | Neue 2-acylpyrrolidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel sowie deren verwendung |
| PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| FR2665898B1 (fr) * | 1990-08-20 | 1994-03-11 | Sanofi | Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| FR2711140B1 (fr) * | 1993-10-12 | 1996-01-05 | Sanofi Sa | 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant. |
-
2003
- 2003-03-13 AR ARP030100880A patent/AR038967A1/es unknown
- 2003-03-17 SI SI200331966T patent/SI1487802T1/sl unknown
- 2003-03-17 CA CA2462694A patent/CA2462694C/en not_active Expired - Fee Related
- 2003-03-17 EP EP03714961A patent/EP1487802B1/en not_active Expired - Lifetime
- 2003-03-17 RU RU2004114262/04A patent/RU2304578C2/ru not_active IP Right Cessation
- 2003-03-17 KR KR10-2004-7014581A patent/KR20040106290A/ko not_active Application Discontinuation
- 2003-03-17 AT AT03714961T patent/ATE493390T1/de active
- 2003-03-17 MX MXPA04004743A patent/MXPA04004743A/es active IP Right Grant
- 2003-03-17 BR BR0306149-3A patent/BR0306149A/pt not_active IP Right Cessation
- 2003-03-17 CN CNB038015668A patent/CN100509788C/zh not_active Expired - Fee Related
- 2003-03-17 ES ES03714961T patent/ES2358894T3/es not_active Expired - Lifetime
- 2003-03-17 JP JP2003576406A patent/JP4484525B2/ja not_active Expired - Fee Related
- 2003-03-17 AU AU2003219165A patent/AU2003219165B2/en not_active Ceased
- 2003-03-17 DK DK03714961.4T patent/DK1487802T3/da active
- 2003-03-17 US US10/490,549 patent/US7186741B2/en not_active Expired - Fee Related
- 2003-03-17 PT PT03714961T patent/PT1487802E/pt unknown
- 2003-03-17 UA UA20041008453A patent/UA77775C2/uk unknown
- 2003-03-17 WO PCT/EP2003/050064 patent/WO2003078400A1/en active Application Filing
- 2003-03-17 PL PL03371440A patent/PL371440A1/xx not_active Application Discontinuation
- 2003-03-17 IL IL16094403A patent/IL160944A0/xx unknown
- 2003-03-17 DE DE60335525T patent/DE60335525D1/de not_active Expired - Lifetime
-
2004
- 2004-03-19 HR HR20040275A patent/HRP20040275A2/hr not_active Application Discontinuation
- 2004-06-15 ZA ZA200404741A patent/ZA200404741B/en unknown
- 2004-10-15 NO NO20044405A patent/NO20044405L/no not_active Application Discontinuation
-
2005
- 2005-04-14 HK HK05103186.3A patent/HK1070646A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04004743A (es) | 2004-08-02 |
| CA2462694A1 (en) | 2003-09-25 |
| CN100509788C (zh) | 2009-07-08 |
| NO20044405L (no) | 2004-10-15 |
| PT1487802E (pt) | 2011-03-11 |
| AU2003219165B2 (en) | 2008-03-13 |
| ES2358894T3 (es) | 2011-05-16 |
| JP2005527528A (ja) | 2005-09-15 |
| CN1592742A (zh) | 2005-03-09 |
| RU2304578C2 (ru) | 2007-08-20 |
| BR0306149A (pt) | 2004-10-19 |
| EP1487802B1 (en) | 2010-12-29 |
| DE60335525D1 (de) | 2011-02-10 |
| EP1487802A1 (en) | 2004-12-22 |
| AU2003219165A1 (en) | 2003-09-29 |
| HK1070646A1 (en) | 2005-06-24 |
| AR038967A1 (es) | 2005-02-02 |
| CA2462694C (en) | 2010-08-10 |
| ZA200404741B (en) | 2005-08-29 |
| PL371440A1 (en) | 2005-06-13 |
| HRP20040275A2 (en) | 2004-08-31 |
| JP4484525B2 (ja) | 2010-06-16 |
| SI1487802T1 (sl) | 2011-04-29 |
| DK1487802T3 (da) | 2011-04-04 |
| IL160944A0 (en) | 2004-08-31 |
| US20040242493A1 (en) | 2004-12-02 |
| US7186741B2 (en) | 2007-03-06 |
| ATE493390T1 (de) | 2011-01-15 |
| KR20040106290A (ko) | 2004-12-17 |
| WO2003078400A1 (en) | 2003-09-25 |
| RU2004114262A (ru) | 2005-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2212007C (en) | Pyridonecarboxylic acid derivatives substitued by a bicyclic amino group | |
| PT97993B (pt) | Processo para a preparacao de derivados de amidas ciclicas e de composicoes farmaceuticas que os contem | |
| WO2014049133A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
| AU2022238441B2 (en) | Derivatives of substituted morpholines and uses thereof | |
| UA77775C2 (en) | 2,3 diaril-pyparazolidine derivatives inhibiting enzymes degrading neurotensin, pharmaceutical conmposition | |
| ES2383799T3 (es) | Procedimiento para la preparación del estereoisómero de glicopirronio con configuración R,R (o S,S) | |
| UA75892C2 (en) | Chromanone derivatives and a method for the preparation thereof | |
| GB1598667A (en) | 1,3-dioxolane derivatives and their use in the preparation of 1-amino-3-aryloxy-2-propanols | |
| EP1777213A1 (en) | Production method of aminochlorohydrin sulfate | |
| US11091436B2 (en) | Process for the separation of optical isomers of racemic 3-alkylpiperidine-carboxylic acid ethyl esters | |
| SK302000A3 (en) | Method for preparing alkyloxy furanone derivatives, compounds obtained by said method and use of said compounds | |
| AT407638B (de) | Verfahren zur selektiven reduktion von chiralen alpha- oder beta-ketoestern mit nabh4 und (d)- oder (l)- weinsäure | |
| WO2006051000A2 (en) | Method for preparing diastereoisomers of 4-hydroxy isoleucine | |
| WO2005013909A2 (en) | Novel cathepsin k inhibitors | |
| CA3171651A1 (en) | Methods of preparing chiral benzodiazepinone derivatives | |
| EP1088825B1 (en) | Enantiomerically pure substituted oxaaza compounds, salts of the same, and processes for the preparation of both | |
| ES2215922T3 (es) | Procedimiento para la preparacion de 9,10 dihidropirrolo(2,1-b)(1,3)benzotiacepinas aminosustituidas en la posicion 9'. | |
| MXPA00000506A (es) | Procedimiento para la preparacion de los derivados aminados de la alquiloxifuranona, compuestos obtenidos por este procedimiento y uso de los mismos | |
| WO2014189646A1 (en) | Processes and intermediates useful for preparing cysteine protease inhibitors |